Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry

BACKGROUND: Real-world studies assessing the comparative effectiveness of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) as first-line targeted therapy are scarce. We analyzed the real-world persistence and effectiveness of etanercept (ETN), adalimumab (ADA), and J...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappas, Dimitrios A., O’Brien, Jacqueline, Guo, Lin, Shan, Ying, Baker, Joshua F., Kricorian, Gregory, Stryker, Scott, Collier, David H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492389/
https://www.ncbi.nlm.nih.gov/pubmed/37689684
http://dx.doi.org/10.1186/s13075-023-03120-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492389/
https://www.ncbi.nlm.nih.gov/pubmed/37689684
http://dx.doi.org/10.1186/s13075-023-03120-9

Ejemplares similares